Please assess the completion status of the following clinical trial:

Trial Title: Somatostatin In Patients With Autosomal Dominant Polycystic Kidney Disease And Moderate To Severe Renal Insufficiency

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> 18 years~* Clinical and ultrasound diagnosis of ADPKD~* Estimated GFR between 15 and 40 ml/min/1.73m2 (by the MDRD 4 variable equation)~* Written informed consent~Exclusion Criteria:~* 24-h Urinary protein excretion rate \>3g (suggestive of a concomitant glomerular disease that could benefit of specific therapy)~* Symptomatic urinary tract lithiasis or obstruction~* Uncontrolled diabetes mellitus (HbA1c \>8%) or hypertension (systolic/diastolic BP \>180/110 mmHg)~* Current urinary tract infection~* Symptomatic biliary tract lithiasis~* Active cancer~* Psychiatric disorders or any condition that might prevent full comprehension of the purposes and risks of the study~* Pregnancy, lactation or child bearing potential and ineffective contraception (estrogen therapy in post menopausal women should not be stopped)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Saline solution. (Type: PLACEBO_COMPARATOR): None
- Octrotide-LAR (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).